Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Combination therapy with acalabrutinib, venetoclax, and obinutuzumab (AVO) is found to be highly active and well tolerated in treatment-naïve patients with chronic lymphocytic leukemia (CLL ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) patients with a new all-tablet treatment showing impressive results.

The study enrolled 523 patients with untreated CLL, randomly assigning them to receive either MRD-driven ibrutinib-venetoclax therapy or standard FCR. After a median follow-up of 43.7 months ...

The molecular mechanisms underlying resistance to therapy in Chronic lymphocytic leukemia (CLL) remain to be explored. Here, the authors perform multi-omics analysis in a mouse model of ibrutinib ...

Despite bendamustine's availability in Europe for 4 decades, the available clinical data shed little light on its role in the treatment of CLL. Adverse effects include myelosuppression and ...

Data are now accumulating on the feasibility of various treatment options even in unfit patients and there is an increased awareness that the chronological age by itself sometimes does not reflect ...

Leqembi and Kisunla represent a great step forward in Alzheimer’s treatment. Still, patients need to jump through logistical hurdles to secure a prescription or insurance coverage. And they have to ...